Skip to content
Screener

Innoviva, Inc. INVA Operating Income

Operating Income at other companies

AbbVie logo
AbbVieABBV
$6.43B+31.4%
Insmed logo
InsmedINSM
-$1.55M+99.5%
Savara logo
SavaraSVRA
-$38.99M-37.1%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$9.48M+34.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$14.36M-541%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative34,57126,41267,00953,903
Research and development5,1907,98310,43112,379
Total operating expenses39,76134,39577,44066,282
Income from operations50,85548,75189,00990,179
Changes in fair values of equity method investments, net(131,834)13,08225,816(467)
Changes in fair values of equity and long-term investments, net(29,153)11,2804,422(54,019)
Interest and dividend income7,5994,92518,5869,463
Interest expense(5,472)(4,663)(10,909)(9,374)

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s operating income?
Innoviva, Inc. (INVA) reported operating income of $50.86M in Q2 2026.
How has Innoviva, Inc.'s operating income changed year-over-year?
Innoviva, Inc.'s operating income increased by 4.3% year-over-year, from $48.75M to $50.86M.
What is the long-term trend for Innoviva, Inc.'s operating income?
Over 3 years (2021 to 2025), Innoviva, Inc.'s operating income has grown at a -24.1% compound annual growth rate (CAGR), from $375.1M to $163.75M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Innoviva, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude